

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 39-232

C# M#

FREEMAN et al

Group Art Unit:


Examiner:

Date: August 7, 2001

Serial No. 09/763,236

Filed: June 11, 2001

Title: DRUG TARGETING

Assistant Commissioner for Patents
Washington, DC 202311635
RECEIVED

AUG 09 2001

TECH CENTER 1600/2900

Sir:

INFORMATION DISCLOSURE STATEMENT

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment 0 minus highest number
previously paid for 20 (at least 20) = 0 x \$ 18.00 \$ 0.00

Independent claims after amendment 0 minus highest number
previously paid for 3 (at least 3) = 0 x \$ 80.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$270.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this
paper and attachment(s) (\$110.00/1 month; \$390.00/2 months; \$890.00/3 months) \$ 0.00

Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00

☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$710.00) \$ 0.00

☐ Please enter the previously unentered, filed

☐ Submission attached

Subtotal \$ 0.00

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: 0.00

TOTAL FEE ENCLOSED \$ 0.00

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
MJW:tat

NIXON & VANDERHYE P.C.
By Atty: Mary J. Wilson, Reg. No. 32,955

Signature: Mary J. Wilson

RECEIVED

AUG 09 2001

TECH CENTER 1600/2900

#6
BP
8-16-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re PATENT APPLICATION OF

FREEMAN et al

Serial No.: 09/763,236

Filed: June 11, 2001

For: DRUG TARGETING



Atty. Ref.: 39-232

Group Art Unit:

Examiner:

* * * * *

August 7, 2001

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of Patents
and Trademarks
Washington, DC 20231

Sir:

Attached is Form PTO-1449 listing the enclosed documents.

This IDS is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to comply fully.

Contingent Request Under Rule 97(c): Should a first action on the merits have been issued on the same day or before this IDS is filed, please accept this IDS under Rule 97(c) and charge the requisite Rule 17(p) fee to our

FREEMAN et al -- Serial No.: 09/763,236

Deposit Account No. 14-1140 (39-232) and proceed to
consider this IDS.

Consideration of the foregoing and enclosures plus the
return of a copy of the herewith Form PTO-1449 with the
Examiner's initials in the left column per MPEP 609 are
earnestly solicited.

Respectfully submitted,

NIXON & VANDERHYE, P.C.

By Mary J. Wilson
Mary J. Wilson
Reg. No. 32,955

MJW:tat

1100 North Glebe Road
8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100